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skewed distribution of health care expense were used to cal-
culate adjusted mean expense for users of each product.
RESULTS: SSRI users included children and adults. Unad-
justed total paid charges were lowest for users of fluoxe-
tine. However, both the paroxetine and sertraline popula-
tions were significantly sicker as measured by the Charlson
comorbidity index (difference  0.11, p  0.05). Adjusted
for age, gender, and comorbidities, the mean paid charges
were 15% higher for paroxetine (p  .001) compared to
fluoxetine and not significantly different for sertraline
compared to fluoxetine. When total pharmacy charges are
added to the non-pharmacy charges, the paroxetine is
20% and sertraline is 27% lower than fluoxetine. Users of
paroxetine are about 50% more likely to switch among
the SSRIs. Switchers have 34% higher total charges.
CONCLUSIONS: The use of SSRIs represents an impor-
tant and growing portion of medical expense. This paper
illustrates that total medical care cost should be used in
making population-level treatment choices.
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OBJECTIVES: The Schizophrenia Care and Assessment
Program (SCAP) is a prospective observational study estab-
lished in the US and Australia to comprehensively measure
characteristics of care for schizophrenia patients in actual
clinical practice while comparing a wide range of clinical,
humanistic, and economic outcomes among older and
newer medications. A feasibility study was conducted to in-
vestigate the potential for adapting SCAP to Western Euro-
pean countries and to determine appropriate study design.
METHODS: The feasibility study was carried out in sev-
eral countries in Europe and included (1) interviews with
providers and planners of healthcare in national associa-
tions of psychiatrists, medical associations and national
and regional government (2) literature searches on a range
of aspects and outcomes of schizophrenia and (3) inter-
views to assess the key operational aspects of conducting a
SCAP study in representative clinical sites. 
RESULTS: The feasibility study indicated that a UK-SCAP
would capture the treatment and budgetary issues raised by
UK prescribers and administrators. The wide range of out-
comes assessments in SCAP (including sociodemographics,
clinical status and treatments, functional status, general
health status, quality of life, resource utilisation and carer
burden) will distinguish the study and complement data
from clinical trials. UK-SCAP will enroll approximately
600 inpatients and outpatients (limited exclusion criteria)
from late-1999 and will follow this cohort for 3 years. The
primary outcomes measurement tools will be the SCAP in-
strument, developed from items derived from established
measures and validated in the US SCAP study.
CONCLUSION: It is important to complement informa-
tion from randomized clinical trials with information from
“real life” settings. As new drug therapies have shown
promise for improved treatment of schizophrenia, more
research is needed to understand the clinical, humanistic,
and economic opportunities of these therapies.
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Series of N-of-1 trials have long been used to help decide the
usefulness of interventions in psychology, often where con-
ventional trial designs are impractical or unethical. Recently,
N-of-1 trials have been adopted to make decisions on the
usefulness of a proven therapy in individual patients. Their
use is increasing because many people do not respond to a
proven treatment, a greater desire to individualize therapy to
enhance the risk/benefit ratio, and cost-containment pres-
sures. N-of-1 trials reduce between-subject variability. They
are useful in chronic diseases, where the effects of the active
treatment are unlikely to carry-over to the next treatment
period. N-of-1 trials provide a unique vehicle for the collec-
tion of economic data. Unlike most crossover trials, N-of-1
trials typically involve repeated episodes of the alternative
treatments being administered over consecutive cycles. This
means that each patient in a series of N-of-1 trials provides
multiple observations for each treatment considered. As the
required sample size for the economic components of clini-
cal trials have been shown to be large, such trials offer an al-
ternative to large samples that may be unfeasible. In addi-
tion, N-of-1 trials provide the means to estimate individual
cost-effectiveness ratios, which may be incorporated into the
patient, or clinician, decision making process. The problem
of follow-up must be addressed, particularly as evaluations
measuring QALYs necessarily require a life time horizon.
However, if an intermediate outcome can be identified, en-
abling extrapolation, then this problem can be addressed.
Specific examples of the use of this design will be illustrated
from the field of dementia, where the ‘number needed to
treat’ to obtain benefit in one patient is high from symptom-
atic improvement by approved cholinergic agents. The role
of economic data from N-of-1 trials to help drug develop-
ment will also be discussed.
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